Du, Yujing
Yu, Lixiu
Deng, Bin
Li, Qinying
Hu, Junrui
Li, Linjie
Xu, Yusen
Song, Liangwei
Xie, Fang
Wang, Yinghui
Chen, Yuhao
Liu, Chengxin
Zhai, Xuejia
Lu, Yongning http://orcid.org/0000-0001-7172-9913
Funding for this research was provided by:
Key Research and Development Plan of Hubei Province (2023BCB030)
Chinese Pharmaceutical Association (CPA-Z05-ZC-2022-002)
Article History
Accepted: 26 March 2024
First Online: 13 April 2024
Declarations
:
: This work was supported by the Key Research and Development Plan of Hubei Province, China (2023BCB030) and the Chinese Pharmaceutical Association (CPA-Z05-ZC-2022-002). The study was also supported by Shandong Luoxin Pharmaceutical Group Co., Ltd.
: Liangwei Song, Fang Xie, Yinghui Wang, Yuhao Chen, and Chengxin Liu are employees of Shandong Luoxin Pharmaceutical Group Co., Ltd. They have no other relevant disclosures to declare. Yujing Du, Lixiu Yu, Bin Deng, Qinying Li, Junrui Hu, Linjie Li, Yusen Xu, Xuejia Zhai, and Yongning Lu have no relevant conflicts of interest to declare.
: The data presented in this study are available from the corresponding author on reasonable request.
: The study was approved by the Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology [approval no. (2022) 0945] on 10 January 2023. The study was performed in accordance with the Good Clinical Practice standards of China National Medical Products Administration, the current Declaration of Helsinki (as revised in 2013), and relevant regulations.
: Informed consent was obtained from all individual participants included in this study.
: Conceptualization: All authors. Methodology: BD, QL, JH. Formal analysis and investigation: LL, YX. Writing – original draft preparation: YD. Writing – review and editing: LY, YW, YC, CL, XZ, YL. Funding acquisition: XZ, YL. Resources: LS, FX. Supervision: XZ, YL. Project administration: YL. All authors read and approved the final manuscript.
: Not applicable.
: Not applicable.